Vanda Pharmaceuticals (NASDAQ: VNDA) opened some 45% higher today after the biotech firm said it has received the FDA’s approval for its treatment of schizophrenia and bipolar I disorder.
The BYSANTI (milsaperidone) announcement is a welcome reprieve for VNDA that’s been under pressure this year as investors weighed “disappointing” Q4 earnings against a backdrop of clinical uncertainty.
However, while the “New Chemical Entity” (NCE) status and patent protection through 2044 offer a long-term runway, it’s reasonable to question whether Vanda Pharmaceuticals’ stock price rally is sustainable or a classic “sell the news” mirage.
VNDA shares may just be seeing a short squeeze
While the 44% pop makes for a glowing headline, the underlying mechanics suggest the rally may be driven more by technical desperation than fundamental shift.
Before the BYSANTI milestone, Vanda Pharmaceuticals was effectively a “penny stock” – at least for institutional investors – burdened by an alarming short interest of over 3.2 million shares.
With a relatively low float, the sudden influx of positive news likely “forced” short sellers to look for an exit, triggering a classic short squeeze.
Since such rallies are often fuelled by forced closing of bearish positions instead of long-term “buy and hold” conviction, they’re notoriously fragile.
As the squeeze exhausts, VNDA stock risks a rapid “mean reversion,” leaving retail investors who “chased the green” holding the bag on a cooling asset.
BYSANTI approval is more redundant than innovative
A closer look at the “innovation” behind BYSANTI suggests the enthusiasm might be overblown.
BYSANTI’s active mechanism is fundamentally tied to “iloperidone” – the same active ingredient found in Vanda’s existing drug, Fanapt. In fact, milsaperidone rapidly converts into iloperidone once ingested.
While the NCE status provides a fresh patent moat until 2044, the clinical reality is that BYSANTI is largely a “metabolic twin” of a drug that has been on the market for years.
This raises significant commercial hurdles; insurance payers are increasingly “resistant” to high-priced “new” versions of existing therapies.
And with the antipsychotic market saturated by low-cost generics, Vanda Pharmaceuticals shares face an uphill battle in proving BYSANTI offers enough clinical differentiation to justify premium pricing and gain meaningful market share.
How to play Vanda Pharmaceuticals stock at current levels
What’s also worth mentioning is that Vanda’s broader financial health remains a point of “serious concern” as well.
The company reported a staggering net loss in the fourth quarter of 2025, significantly missing analyst estimates with an EPS surprise of -84%.
Total revenues have shown signs of stagnation, and the company recently had to record a massive $113.7 million non-cash charge related to tax asset valuation allowances.
Furthermore, while the NCE status protects BYSANTI – Vanda Pharmaceuticals Inc’s other legacy products face the “patent cliff” that is currently ravaging the small-molecule sector in 2026.
With cash reserves dwindling by over $100 million in the past year, the company may be “forced” to dilute shareholders through a secondary offering to fund the Q3 2026 commercial launch, making the current VNDA share price a high-risk entry point for new investors.
The post Vanda stock’s explosive rally may be more hype than substance appeared first on Invezz
